Lanean...
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade in Solid Malignancies
There have been unprecedented advances in the treatment of cancer through the use of immunotherapy, with several agents now FDA-approved for use in widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory...
Gorde:
| Argitaratua izan da: | Ann Surg Oncol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105272/ https://ncbi.nlm.nih.gov/pubmed/29500764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-018-6379-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|